ATE310957T1 - Vorhersagen ueber von diabetes beeintraechtigte wundheilung - Google Patents

Vorhersagen ueber von diabetes beeintraechtigte wundheilung

Info

Publication number
ATE310957T1
ATE310957T1 AT00916443T AT00916443T ATE310957T1 AT E310957 T1 ATE310957 T1 AT E310957T1 AT 00916443 T AT00916443 T AT 00916443T AT 00916443 T AT00916443 T AT 00916443T AT E310957 T1 ATE310957 T1 AT E310957T1
Authority
AT
Austria
Prior art keywords
wound healing
diabetic
diabetes
diabetic patients
impaired
Prior art date
Application number
AT00916443T
Other languages
English (en)
Inventor
Joseph V Boykin Jr
Original Assignee
Joseph V Boykin Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph V Boykin Jr filed Critical Joseph V Boykin Jr
Application granted granted Critical
Publication of ATE310957T1 publication Critical patent/ATE310957T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT00916443T 1999-03-19 2000-03-17 Vorhersagen ueber von diabetes beeintraechtigte wundheilung ATE310957T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12528499P 1999-03-19 1999-03-19
US09/516,584 US6312663B1 (en) 1999-03-19 2000-03-01 Prediction of diabetes impaired wound healing by urinary nitrate assay
PCT/US2000/007028 WO2000057190A2 (en) 1999-03-19 2000-03-17 Prediction of diabetes impaired wound healing

Publications (1)

Publication Number Publication Date
ATE310957T1 true ATE310957T1 (de) 2005-12-15

Family

ID=26823428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916443T ATE310957T1 (de) 1999-03-19 2000-03-17 Vorhersagen ueber von diabetes beeintraechtigte wundheilung

Country Status (10)

Country Link
US (2) US6312663B1 (de)
EP (1) EP1163528B1 (de)
JP (1) JP3790107B2 (de)
AT (1) ATE310957T1 (de)
AU (1) AU776840B2 (de)
CA (1) CA2366080A1 (de)
DE (1) DE60024240T2 (de)
ES (1) ES2253211T3 (de)
MX (1) MXPA01009460A (de)
WO (1) WO2000057190A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6436366B2 (en) * 1999-03-19 2002-08-20 Joseph V. Boykin, Jr. Prediction of wound healing by urinary nitrate assay
DK1420774T3 (da) * 2001-08-31 2008-11-24 Australian Biomedical Company Fremstilling og diabetisk anvendelse af gibberelliner
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
AU2003295892A1 (en) * 2002-11-20 2004-06-15 Jr. Joseph V. Boykin Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability
ATE474604T1 (de) * 2002-12-02 2010-08-15 Anges Mg Inc Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen
US20060121620A1 (en) * 2004-12-06 2006-06-08 Basant Bhandari Nitrate/nitrite assay reagents, kit, and method of use
US20060121621A1 (en) * 2004-12-06 2006-06-08 Basant Bhandari Nitrate/nitrite assay reagents, kit, and method of use
EP1888510A4 (de) 2005-05-27 2013-01-16 Univ North Carolina Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
GB0817966D0 (en) * 2008-10-02 2008-11-05 Glasgow Health Solutions Ltd Assay
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
US10335412B2 (en) 2013-04-10 2019-07-02 Energenesis Biomedical Co., Ltd Method for activating AMPK and the use of adenine
US9492374B2 (en) 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
US10500206B2 (en) 2017-03-13 2019-12-10 Energenesis Biomedical Co., Ltd. Method for enhancing wound healing by administrating adenine
RU2687978C1 (ru) * 2018-10-10 2019-05-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ прогнозирования тяжелого течения диабетической полинейропатии и развития синдрома диабетической стопы

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912114A (en) * 1997-09-12 1999-06-15 Johnson & Johnson Medical, Inc. Wound diagnosis by quantitating cortisol in wound fluids

Also Published As

Publication number Publication date
WO2000057190A3 (en) 2000-12-14
JP2002540404A (ja) 2002-11-26
ES2253211T3 (es) 2006-06-01
US20010048915A1 (en) 2001-12-06
US6344181B2 (en) 2002-02-05
AU776840B2 (en) 2004-09-23
JP3790107B2 (ja) 2006-06-28
AU3754900A (en) 2000-10-09
EP1163528A2 (de) 2001-12-19
WO2000057190A2 (en) 2000-09-28
DE60024240T2 (de) 2006-07-20
DE60024240D1 (de) 2005-12-29
MXPA01009460A (es) 2003-08-20
US6312663B1 (en) 2001-11-06
CA2366080A1 (en) 2000-09-28
EP1163528B1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE310957T1 (de) Vorhersagen ueber von diabetes beeintraechtigte wundheilung
Kai et al. Accelerated wound healing on skin by electrical stimulation with a bioelectric plaster
Tang et al. Multifunctional dressing for wound diagnosis and rehabilitation
Sibbald et al. Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care.
Barnea et al. A review of the applications of the hydrofiber dressing with silver (Aquacel Ag®) in wound care
Viswanathan et al. Efficacy of recombinant human epidermal growth factor (Regen-D 150) in healing diabetic foot ulcers: a hospital-based randomized controlled trial
Fong et al. Nanocrystalline silver dressings in wound management: a review
Gethin et al. The impact of Manuka honey dressings on the surface pH of chronic wounds
Bohn et al. Ovine-based collagen matrix dressing: next-generation collagen dressing for wound care
Haryanto et al. Relationship between maceration and wound healing on diabetic foot ulcers in Indonesia: a prospective study
Solway et al. A parallel open‐label trial to evaluate microbial cellulose wound dressing in the treatment of diabetic foot ulcers
WO2001013926A3 (en) Superoxidized water based on hypochlorous acid for the treatment of wounds
NO20006336L (no) Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse
Kumar et al. Effect of limited access dressing on surface pH of chronic wounds
Thomason et al. Silver oxysalts promote cutaneous wound healing independent of infection
ATE207758T1 (de) Verwendung von igf-1
Morilla‐Herrera et al. Effectiveness of a hydrophobic dressing for microorganisms’ colonization of vascular ulcers: Protocol for a randomized controlled trial (CUCO‐UV Study)
Davis Smart bandage technologies: design and application
ATE485523T1 (de) Vorhersagen der wundheilung durch harnnitrat- bestimmung
Akaza et al. Effects of Propionibacterium acnes on various mRNA expression levels in normal human epidermal keratinocytes in vitro
Renner et al. Transplantation of chronic wounds with epidermal sheets derived from autologous hair follicles—the Leipzig experience
Irawan et al. Hypochlorous acid for wound healing in diabetic rats: effect on MMP-9 and histology
Varani et al. All-trans retinoic acid improves structure and function of diabetic rat skin in organ culture
Li et al. Conformable electrochemical devices for closed-loop wound management
Hunt et al. Ultraviolet B Light Stimulates lnterleukin‐20 Expression by Human Epithelial Keratinocytes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties